Beta-aminoisobutyric acid (BAIBA) as an anti-obesity intervention
Beta-aminoisobutyric acid (BAIBA), a metabokine derived from skeletal muscle during exercise, is proposed as an orally available anti-obesity treatment. It increases basal energy expenditure, promotes adipose tissue browning, and maintains muscle mass, offering a novel weight-loss solution.
Overview
Beta-aminoisobutyric acid (BAIBA) is a promising compound derived from skeletal muscles during exercise, proposed as an innovative anti-obesity intervention. Unlike traditional weight-loss treatments, BAIBA not only reduces adiposity but also maintains or increases skeletal muscle mass. This dual action is crucial as it addresses common issues associated with weight loss, such as muscle loss and dysfunction. BAIBA's ability to increase basal energy expenditure and improve glucose tolerance makes it a potential game-changer in the fight against obesity, providing a physiological and well-tolerated solution.
Technical specifications
- Origin: Produced by skeletal muscles during exercise.
- Functionality: Increases basal energy expenditure, induces adipose tissue browning, and activates hepatic fatty acid beta-oxidation.
- Benefits:
- Reduces weight gain and adiposity.
- Maintains or increases skeletal muscle mass.
- Improves muscle contractile and mitochondrial function.
- Enhances glucose tolerance.
- Administration: Orally available as a water-soluble compound.
- Validation: Proof-of-concept study involving 20 overweight/obese volunteers to assess impact on energy expenditure and muscle mass.
Technology readiness level
This technology is at a Technology Readiness Level (TRL) of 4, indicating that it is in the experimental medicine phase with ongoing proof-of-concept studies. The upcoming study will further validate BAIBA's efficacy in human subjects, building on successful results from mouse models and cell lines.
About University of Leeds
The University of Leeds is a comprehensive, research‑intensive public university serving a large student body and global partner network. Industry partners engage through an on‑campus innovation hub offering flexible workspace, shared labs and prototyping, and options to co‑locate with academic experts. The university’s integration with major NHS teaching hospitals in the city enables clinical research, validation, and translation. Research is backed by competitive funding from UK Research and Innovation (UKRI) councils and the National Institute for Health and Care Research, with additional European and industry support. A dedicated technology transfer office manages IP, licensing, and spinouts, with partnership models and professional education tailored for corporate R&D.
Inquire about this partnering listing
Industry applications
delivered to your inbox.